Welcome to our dedicated page for Addus HomeCare SEC filings (Ticker: ADUS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Addus HomeCare Corporation filings document a home care provider with personal care, hospice and home health operations. Form 8-K reports furnish quarterly and annual results of operations, Regulation FD disclosures and exhibit press releases, while amended 8-K filings provide acquisition-related financial statements and pro forma information for the completed purchase of Gentiva's personal care business by Addus HealthCare, a wholly owned subsidiary.
Proxy and annual-meeting filings cover board elections, auditor ratification, executive compensation votes and related governance disclosures. The filing record also includes capital-structure, material-event and shareholder-vote disclosures for the company's common stock.
Heather Brianne Dixon, a named officer of Addus HomeCare Corp (ADUS), reported an acquisition on 09/15/2025 of 28,370 shares of the issuer's common stock at a reported price of $0. Following the reported transaction, Ms. Dixon beneficially owns 32,189 shares, held directly. The filing includes an explanatory note that the newly reported shares vest in equal installments on September 15, 2026, September 15, 2027, and September 15, 2028, subject to customary continued-service provisions and acceleration on a change in control. The Form 4 was signed by an attorney-in-fact on 09/16/2025.
Addus HomeCare Corp (ADUS) Form 3: Heather Brianne Dixon, listed at 6303 Cowboys Way, Suite 600, Frisco, TX 75034, filed an initial Section 16 beneficial ownership statement reporting 3,819 shares of Common Stock held directly. The Form 3 is dated for the event on 09/15/2025 and was signed by an attorney-in-fact on 09/16/2025. Her relationship to the issuer is shown as an Officer (President and Chief Operating).
Addus HomeCare Corp. (ADUS) insider filing shows W. Bradley Bickham, the company's President and COO, reported a sale of 4,000 shares of common stock on 09/02/2025 at a weighted-average price of $115.75. After the sale he beneficially owned 37,605 shares. The Form 4 was filed as a single-person report and was signed by an attorney-in-fact for Mr. Bickham on 09/03/2025. The filing discloses the sale prices ranged from $115.48 to $116.14.
R. Dirk Allison, Chairman and CEO of Addus HomeCare (ADUS), reported multiple transactions on 09/02/2025. The filing shows acquisition of 25,000 shares via exercise of employee stock options at a $19.71 exercise price and two open-market disposals totaling 25,000 shares sold at weighted-average prices of $115.72 and $116.34. After these transactions the reporting person beneficially owned 166,461 shares directly. The filing notes all options are fully vested and provides weighted-average price ranges for the sales.
Addus HomeCare Corp. (ADUS) Form 144 shows a proposed sale of 4,000 common shares through Morgan Stanley Smith Barney on 09/02/2025 on NASDAQ, with an aggregate market value of $462,982.40 and 18,407,239 shares outstanding. The filing details that the shares were received as restricted stock in four grants between 03/02/2019 and 03/02/2022 totaling 4,000 shares. It also discloses a prior sale by the same person of 9,000 common shares on 08/13/2025 for gross proceeds of $1,038,105.91. The filer certifies no undisclosed material adverse information.
Addus HomeCare Corp. (ADUS) Form 144 notifies a proposed sale of 25,000 common shares by an identified seller through Morgan Stanley Smith Barney on Nasdaq with an aggregate market value of $2,895,722.50. The shares were acquired and are proposed to be sold on 09/02/2025 following a stock option exercise paid in cash. The filer also discloses a prior sale by the same person of 25,000 shares on 08/20/2025 for gross proceeds of $2,873,862.50. The notice includes the seller’s representation that they are not aware of undisclosed material adverse information about the issuer.
Addus HomeCare Corporation filed a Form S-3 shelf registration to register an indeterminate maximum aggregate amount of common stock, preferred stock, warrants and units for offer and sale from time to time after the effective date as a well-known seasoned issuer.
The prospectus permits concurrent resale by selling stockholders to be named in any prospectus supplement and states that any proceeds from sales by selling stockholders will not be received by the company unless an applicable prospectus supplement indicates otherwise. As of August 20, 2025, the company had 40,000,000 shares of common stock authorized and 18,432,157 shares of common stock outstanding.
Addus HomeCare Corporation amended its Current Report to provide additional financial disclosure related to a completed acquisition. The company reports that on December 2, 2024 its subsidiary, Addus HealthCare, Inc., completed the acquisition of the personal care business of Curo Health Services, LLC (doing business as Gentiva). This Amendment No. 2 adds unaudited financial statements of the acquired business for the year-to-date ended December 1, 2024, and references an unaudited pro forma condensed combined statement of operations for the same period filed as Exhibit 99.1. The filing states that all other disclosures in the prior amended report remain unchanged.
Addus HomeCare Corp. (ADUS) insider filing: Brian Poff, EVP and Chief Financial Officer, reported sales of company common stock on 08/25/2025. He sold 4,106 shares at a weighted-average price of $116.55 (sales ranged $115.76–$116.73) and 3,633 shares at a weighted-average price of $117.13 (sales ranged $116.78–$117.43). After these transactions he beneficially owned 56,980 shares. The Form 4 is signed by Mr. Poff on 08/26/2025 and discloses that the shares were sold in multiple transactions; the filer offers to provide detailed per-price quantities on request.
Addus HomeCare Corp. (ADUS) Form 144 notifies the proposed sale of 7,739 common shares through Morgan Stanley Smith Barney on 08/25/2025 on NASDAQ with an aggregate market value of $904,114.87. The filing shows 18,407,239 shares outstanding. The shares to be sold were recently acquired as restricted stock from the issuer on 02/22/2025 (2,792 shares), 02/23/2025 (1,881 shares) and 02/24/2025 (3,066 shares), with payment noted as Not Applicable. The filer reports no securities sold in the past three months and includes the standard representation that the seller is not aware of undisclosed material adverse information.